logo

For the Inventor, By the Inventor

Pittsburgh, PA, United States of America

Wei Qian

This inventor holds 5 USPTO granted patents. Top assignee: University of Pittsburgh. Active years: 2014-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wei Qian. Retrieved from https://idiyas.com/inventor/wei-qian-gce6c4lp

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5

% Patents Active = 100.0

Average Co-Inventor Count = 2.7

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:

goldMedal5 out of 1,960 
 
University of Pittsburgh
 patents

Years Active: 2014-2021

Loading Chart...
5 patents (USPTO):Explore Patents
1. 10968196 - Substituted β-lapachones for treating cancer (2021-04-06),
2. 10478437 - Combination therapy to enhance the anticancer efficacy of platinum drugs (2019-11-19),
3. 10450289 - Substituted β-lapachones for treating cancer (2019-10-22),
4. 9492450 - Inhibition of dynamin related protein 1 to promote cell death (2016-11-15),
5. 8759097 - Inhibition of dynamin related protein 1 to promote cell death (2014-06-24),

Title: Innovations in Cancer Treatment by Wei Qian

Introduction

Wei Qian is a notable inventor based in Pittsburgh, PA (US), recognized for his contributions to cancer treatment through innovative pharmaceutical compositions. With a total of 5 patents, his work focuses on developing compounds that target cancer and neurodegenerative disorders.

Latest Patents

Wei Qian's latest patents include significant advancements in cancer treatment. One of his notable inventions is related to substituted β-lapachones for treating cancer. This patent describes compounds that are useful in treating cancer and neurodegeneration. The compounds comprise a β-lapachone or β-lapachone derivative tricyclic ortho-naphthoguinone moiety linked to a mitochondria-targeting moiety. Pharmaceutical compositions are also provided, along with methods of treatment for cancer and neurodegenerative disorders.

Another important patent involves combination therapy to enhance the anticancer efficacy of platinum drugs. This invention relates to compositions and methods for reducing cell proliferation and promoting cell death. It is based on the discovery that certain compounds, when used with a second antiproliferative agent like cisplatin, act synergistically to promote apoptosis in platinum drug-resistant cell lines. This patent provides novel anticancer strategies that could significantly impact treatment outcomes.

Career Highlights

Wei Qian is affiliated with the University of Pittsburgh, where he conducts research and develops innovative solutions for cancer treatment. His work has garnered attention in the scientific community, contributing to advancements in pharmaceutical sciences.

Collaborations

Wei Qian collaborates with esteemed colleagues such as Bennett Van Houten and Peter Wipf. Their combined expertise enhances the research efforts in developing effective cancer therapies.

Conclusion

Wei Qian's innovative work in cancer treatment exemplifies the potential of pharmaceutical research to address critical health challenges. His patents reflect a commitment to improving therapeutic strategies for cancer and neurodegenerative disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…